Skip to main content
. 2019 Jun 13;11(6):823. doi: 10.3390/cancers11060823

Figure 5.

Figure 5

CompC inhibited B16-F1 tumor growth and angiogenesis in C57BL/6 mice. (A,B) Three days after B16-F1 tumor cell injection, vehicle or CompC (2.5 mg/kg/day) was intraperitoneally injected into the tumor-bearing mice. Body weight and tumor volume were measured and plotted in (A,B) respectively. Significant difference between vehicle and CompC injection groups at each day is marked with an asterisk (p < 0.05, Mann-Whitney U test). (C,D) On 14 days after daily injection of vehicle or CompC, tumors were excised and either embedded in paraffin for H&E staining (C) or frozen in Tissue-Tek O.C.T. tissue matrix compound for immunofluorescence staining (D). Tumors stained with H&E (40–100×) or immunostained with (c,d,g,h) or without anti-MECA32 antibodies (negative control: a, b, e, and f) in the presence of FITC-conjugated secondary antibodies and 4′,6-diamidino-2-phenylindole (DAPI) stain were photographed (400×).